Literature DB >> 33513838

Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations.

Yan Jiang1,2, Jean-Richard Eveillard3, Marie-Anne Couturier3, Benoit Soubise1, Jian-Min Chen1, Sujun Gao2, Audrey Basinko4, Frédéric Morel1,4, Nathalie Douet-Guilbert1,4, Marie-Bérengère Troadec1,4.   

Abstract

This study explores the hypothesis that genetic differences related to an ethnic factor may underlie differences in phenotypic expression of myelodysplastic syndrome (MDS). First, to identify clear ethnic differences, we systematically compared the epidemiology, and the clinical, biological and genetic characteristics of MDS between Asian and Western countries over the last 20 years. Asian MDS cases show a 2- to 4-fold lower incidence and a 10-year younger age of onset compared to the Western cases. A higher proportion of Western MDS patients fall into the very low- and low-risk categories while the intermediate, high and very high-risk groups are more represented in Asian MDS patients according to the Revised International Prognostic Scoring System. Next, we investigated whether differences in prognostic risk scores could find their origin in differential cytogenetic profiles. We found that 5q deletion (del(5q)) aberrations and mutations in TET2, SF3B1, SRSF2 and IDH1/2 are more frequently reported in Western MDS patients while trisomy 8, del(20q), U2AF1 and ETV6 mutations are more frequent in Asian MDS patients. Treatment approaches differ between Western and Asian countries owing to the above discrepancies, but the overall survival rate within each prognostic group is similar for Western and Asian MDS patients. Altogether, our study highlights greater risk MDS in Asians supported by their cytogenetic profile.

Entities:  

Keywords:  Asia; ETV6; Europe; IDH1/2; RUNX1; SF3B1; SRSF2; U2AF1; cytogenetics; del(20q), TET2; del(5q), trisomy 8; myelodysplastic syndrome; prognosis; survival; treatments

Year:  2021        PMID: 33513838     DOI: 10.3390/cancers13030481

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Pimjai Niparuck; Pornnapa Police; Phichchapha Noikongdee; Kanchana Siriputtanapong; Nittaya Limsuwanachot; Budsaba Rerkamnuaychoke; Suporn Chuncharunee; Teerapong Siriboonpiputtana
Journal:  Diagn Pathol       Date:  2021-10-31       Impact factor: 2.644

2.  Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.

Authors:  Nehakumari Maurya; Purvi Mohanty; Somprakash Dhangar; Purvi Panchal; Farah Jijina; S Leo Prince Mathan; Chandrakala Shanmukhaiah; Manisha Madkaikar; Babu Rao Vundinti
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

3.  IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes.

Authors:  Junying Wu; Yudi Zhang; Tiejun Qin; Zefeng Xu; Shiqiang Qu; Lijuan Pan; Bing Li; Yujiao Jia; Chengwen Li; Huijun Wang; Qingyan Gao; Wenyu Cai; Jingye Gong; Songyang Zhao; Fuhui Li; Robert Peter Gale; Zhijian Xiao
Journal:  Exp Hematol Oncol       Date:  2022-10-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.